



1614 \$
ABB10010P0750US
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:) Inhibitors of the Endothelin Signalling
Amberg, et al.) Pathway and $\alpha_V\beta_3$ Integrin Receptor
) Antagonists for Combination Therapy
)
Serial No.: 10/089,146) Group Art Unit: 1614
)
Filed: September 16, 2002) Examiner: Maher M. Haddad

RESPONSE TO RESTRICTION REQUIREMENT

BOX NON-FEE
Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Restriction Requirement set forth in the Office Action dated November 17, 2004, Applicants elect the invention of Group II (claims 4-6 and 10) for prosecution in the present application, without traverse.


Applicants reserve the right to file divisional applications to the subject matter of the non-elected claims.

Favorable consideration and allowance of claims 4-6 and 10 is respectfully requested.

If any fees are incurred as a result of the filing of this paper, authorization is given to charge Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER



Martin L. Katz, Reg. No. 25,011

Date: December 21, 2004

Citicorp Center, Suite 3800
500 W. Madison Street
Chicago, IL 60661-2511
(312) 876-1800



ABB10010P0750US

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as first class mail in an envelope addressed to: Commissioner for Patents, Box Non-Fee, on December 21, 2004.

Rebecca J. Willis
Rebecca J. Willis